ACE and Insulin resistance: Pharmacologic measures: treatment with thiazolidinediones (reducing insulin resistance and pro-inflammatory milieu, along with remodeling of the adipose tissue), biguanides (reducing insulin resistance), angiotensin converting enzyme inhibitors or angiotensin receptor blockers (reducing blood pressure, improving glycemia and systemic inflammation) and HMG-CoA reductase inhibitors or statins (systemic inflammation, improving cardiac risk ratios and endothelial function) could be utilized.